GENFLOW BIOSCIENCES PLC (WQ5) - Net Assets
Based on the latest financial reports, GENFLOW BIOSCIENCES PLC (WQ5) has net assets worth €- EUR as of . Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
GENFLOW BIOSCIENCES PLC - Net Assets Trend (None–None)
This chart illustrates how GENFLOW BIOSCIENCES PLC's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for GENFLOW BIOSCIENCES PLC (None–None)
The table below shows the annual net assets of GENFLOW BIOSCIENCES PLC from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to GENFLOW BIOSCIENCES PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
GENFLOW BIOSCIENCES PLC Competitors by Market Cap
The table below lists competitors of GENFLOW BIOSCIENCES PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Edgewater Wireless Systems Inc
V:YFI
|
$8.63 Million |
|
TZ Ltd
AU:TZL
|
$8.64 Million |
|
Patel Integrated Logistics Limited
NSE:PATINTLOG
|
$8.64 Million |
|
Seva Mining Corp.
V:SEVA
|
$8.64 Million |
|
Labrador Gold Corp
V:LAB
|
$8.61 Million |
|
Data Storage Corp
NASDAQ:DTST
|
$8.60 Million |
|
Sonnet Biotherapeutics Holdings Inc
NASDAQ:SONN
|
$8.60 Million |
|
Miraculum SA
WAR:MIR
|
$8.60 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GENFLOW BIOSCIENCES PLC's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares GENFLOW BIOSCIENCES PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently GENFLOW BIOSCIENCES PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares GENFLOW BIOSCIENCES PLC's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $316,397,405
- Average return on equity (ROE) among peers: -814.99%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GENFLOW BIOSCIENCES PLC (WQ5) | €- | N/A | N/A | $8.61 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $24.67 Million |
| PreveCeutical Medical Inc (18H) | $-6.64 Million | 0.00% | 0.00x | $3.34 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $978.02 Million |
| ONCOARENDI THERAP ZY-01 (1B1) | $100.93 Million | -28.11% | 0.11x | $24.94 Million |
| Flerie AB (publ) (1NP1) | $4.20 Billion | -5.43% | 0.01x | $231.62 Million |
| NUFORMIX PLC LS -001 (1RT) | $5.69 Million | -22.04% | 0.06x | $1.53 Million |
| 1S90 (1S90) | $13.78 Million | 0.99% | 9.14x | $70.17 Million |
| Strategic Partners A/S (1TB0) | $9.34 Million | -6708.84% | 17.55x | $3.69 Million |
| Entheon Biomedical Corp. (1XU) | $614.57K | -1386.45% | 0.25x | $502.28K |
| 25K0 (25K0) | $-186.02 Million | 0.00% | 0.00x | $125.12 Million |
About GENFLOW BIOSCIENCES PLC
Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapy targeting the upstream biology of aging in the United Kingdom and Belgium. The company operates as a pre-clinical biotechnology company that focuses on developing biological interventions aimed at tackling the effects of aging, slowing, and halting the aging process, as well as reducin… Read more